Travere Therapeutics (TVTX) Earnings Date, Estimates & Call Transcripts → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free TVTX Stock Alerts $6.75 +0.20 (+3.05%) (As of 05/7/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 1EstimatedActual EPS (May. 6) -$1.76 Missed By -$0.78 Consensus EPS (May. 6) -$0.98 Read Call TranscriptListen to CallLatest SEC 10-Q Filing Get Travere Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for TVTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueTVTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TVTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now Travere Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244($1.20)($0.96)($1.08) Q2 20244($1.04)($0.65)($0.89) Q3 20244($0.94)($0.67)($0.82) Q4 20244($0.80)($0.51)($0.66) FY 202416($3.98)($2.79)($3.45) Q1 20251($0.34)($0.34)($0.34) Q2 20251($0.10)($0.10)($0.10) Q3 20251$0.07$0.07$0.07 Q4 20251$0.14$0.14$0.14 FY 20254($0.23)($0.23) ($0.23)TVTX Earnings Date and InformationTravere Therapeutics last released its earnings data on May 6th, 2024. The reported ($1.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.78. The business earned $41.40 million during the quarter, compared to analyst estimates of $43.46 million. Its quarterly revenue was up 34.0% on a year-over-year basis. Travere Therapeutics has generated ($1.61) earnings per share over the last year (($1.61) diluted earnings per share). Earnings for Travere Therapeutics are expected to grow in the coming year, from ($3.10) to ($1.86) per share. Travere Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off prior year's report dates.Read More Travere Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/1/2024Estimated)------- 5/6/2024Q1 2024($0.98)($1.76)($0.78)($1.76)$43.46 million$41.40 million 2/15/2024Q4 2023($1.27)($1.16)+$0.11($1.14)$41.25 million$45.06 million11/7/2023Q3 2023($1.09)($1.17)($0.08)($4.31)$132.01 million$37.10 million8/3/2023Q2 2023($1.16)($1.13)+$0.03($1.13)$53.93 million$59.70 million5/4/2023Q1 2023($1.18)($1.27)($0.09)($1.27)$50.93 million$56.99 million2/23/2023Q4 2022($1.04)($1.03)+$0.01($1.03)$54.80 million$55.87 million Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/27/2022Q3 2022($0.97)($1.09)($0.12)($1.09)$51.32 million$53.50 million8/4/2022Q2 2022($0.94)($1.05)($0.11)($1.05)$49.33 million$54.17 million5/5/2022Q1 2022($0.85)($1.20)($0.35)($1.20)$51.92 million$48.49 million 2/24/2022Q4 2021($0.72)($0.84)($0.12)($0.84)$56.40 million$57.25 million 10/28/2021Q3 2021($0.72)($0.59)+$0.13($0.59)$60.93 million$68.20 million 7/29/2021Q2 2021($0.73)($0.64)+$0.09($0.64)$50.20 million$54.62 million Travere Therapeutics Earnings - Frequently Asked Questions When is Travere Therapeutics's earnings date? Travere Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates. Learn more on TVTX's earnings history. Did Travere Therapeutics beat their earnings estimates last quarter? In the previous quarter, Travere Therapeutics (NASDAQ:TVTX) missed the analysts' consensus estimate of ($0.98) by $0.78 with a reported earnings per share (EPS) of ($1.76). Learn more on analysts' earnings estimate vs. TVTX's actual earnings. How can I listen to Travere Therapeutics's earnings conference call? The conference call for Travere Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Travere Therapeutics's conference call transcript? The conference call transcript for Travere Therapeutics's latest earnings report can be read online. Read Transcript How can I view Travere Therapeutics's earnings report? Travere Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded annual revenue of $145.24 million. How much profit does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded net income of -$111.40 million. TVTX has generated -$1.61 earnings per share over the last four quarters. What is Travere Therapeutics's EPS forecast for next year? Travere Therapeutics's earnings are expected to grow from ($3.10) per share to ($1.86) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Annexon Earnings Acelyrin Earnings Theravance Biopharma Earnings Larimar Therapeutics Earnings Neurogene Earnings Fulcrum Therapeutics Earnings Entrada Therapeutics Earnings PepGen Earnings Corbus Pharmaceuticals Earnings Korro Bio Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:TVTX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe Gold Grab of the CenturyColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024AltimetryGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
